Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
January 5, 2016British Journal of HaematologyOpen Access

The addition of sirolimus to the graft‐versus‐host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial

View Full Paper
Ask AI
Bookmark
Share

Authors

PAPhilippe ArmandBoston UniversityHKHaesook T. KimDana-Farber Cancer InstituteMSMarie-Michèle SainvilDuke University

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Armand et al. (2016) studied this question.

synapsesocial.com/papers/6a6da0bb8031ec7bb1db63d0https://doi.org/10.1111/bjh.13931
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation2010 · 1,503 citations
  2. 2Phase II Trial of Single-Agent Temsirolimus (CCI-779) for Relapsed Mantle Cell Lymphoma2005 · 520 citations
  3. 3A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation2014 · 35 citations
  4. 4A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma2010 · 300 citations
  5. 5Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft‐<i>versus</i>‐host disease2005 · 184 citations